8 maj, 2018
Chordate enrolls first patients in a randomized, placebo-controlled, double-blind,multicenter study to evaluate the efficacy of intranasal kinetic oscillation stimulation in thetreatment of chronic non-allergic rhinitis
Data Anticipated Q4 2019
Kista, Sweden, May 08, 2018 — Chordate Medical Holding AB’s (publ) (“Chordate”), a specialty medtech company thatfocuses on developing and commercializing neuromodulating treatment systems for treating non-allergic rhinitis andmigraine, today announced that the first patients were enrolled in Chordate’s clinical study of its Kinetic OscillationStimulation System S101 (KOS-treatment), an investigative product, in patients with diagnosed chronic non-allergic rhinitis.“To now get started with the first patients at the University Hospitals in Helsinki and Kuopio, Finland, is very important in ourlong-term securing of scientific evidence. We know from previous studies, and our own and others’ clinical experiences inpractice, that we make significant difference for this very large patient group. We are now building further on this with theaim to produce a clear scientific basis for our continued business journey”, says Anders Weilandt, CEO of Chordate.The randomized, placebo-controlled, double-blind, multicenter study is being conducted at fourteen ENT university clinics inFinland, UK, The Netherlands, Italy and the Czech Republic. Coordinating investigator is Professor Claire Hopkins at GuysHospital, London and study advisor is Professor Mats Holmström at the Karolinska Institute, Stockholm. The study intends toenroll up to 300 subjects and is designed to evaluate the efficacy and safety of the KOS-treatment. The primary endpoint is todetect weekly median change in a set of evaluation criteria from baseline, with a series of two consecutive treatments, untilthe third month follow-up visit. The total follow-up period of each patient is twelve months. Patients in the KOS arm willreceive active treatment from the S101, while patients receiving placebo treatment will be given a validated sham treatmentfrom the same equipment.
For more information, please contact:Anders Weilandt, CEOanders.email@example.comPhone: +46 (0) 733 87 42 77
Information:This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market AbuseRegulation. The information was provided, through the contact person above for publication on May 08, 2018 at. 14:45 CET.TO THE EDITORSAbout ChordateChordate Medical Holding AB (publ) is a medical technology company that during ten years has developed, patented and CEmarkeda new treatment method for chronic nasal congestion through nerve stimulation. The company sells its productsystem including treatments through its own sales organization as well as distributors to clinics and hospitals, which in theirturn treat patients. Read more at www.chordate.com. Mangold Fondkommission AB, tel. +46 8 5030 1550, is the company’smentor and liquidity guarantee at NGM Nordic MTF.
Vill du läsa våra pressmeddelanden finns de under Investor relations eller via länken nedan.
För frågor om Chordates aktiekurs eller andra investeringsrelaterade ämnen, vänligen se om svaret finns här.
För frågor om K.O.S-behandlingens medicinska effekter, vänligen se om svaret finns här.
För att komma i kontakt med Chordate gällande andra frågor, använd formuläret här bredvid. Vi gör vårt bästa för att svara så snabbt som möjligt.
Informationen hanteras enligt vår integritetspolicy.
Vi använder kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Läs mer om cookies på Chordates webbplats.